Re-calculating! Navigating through the osteosarcoma treatment roadblock
| Autor: | Utset-Ward Tj, McGuire Jm, Lynch Cc, Reed Dm |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Antineoplastic Agents Disease Metastasis 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Tumor Microenvironment Animals Humans Survival rate Etoposide Pharmacology Osteosarcoma Ifosfamide business.industry medicine.disease Surgery Clinical trial Survival Rate 030104 developmental biology 030220 oncology & carcinogenesis Methotrexate business medicine.drug Signal Transduction |
| Zdroj: | Pharmacological research. 117 |
| ISSN: | 1096-1186 |
| Popis: | The survival rates for patients with osteosarcoma have remained almost static for the past three decades. Current standard of care therapy includes chemotherapies such as doxorubicin, cisplatin, and methotrexate along with complete surgical resection and surgery with or without ifosfamide and etoposide for relapse, though outcomes are hoped to be improved through clinical trials. Additionally, increased understanding of the genetics, signaling pathways and microenvironmental factors driving the disease have led to the identification of promising agents and potential paths towards translation of an exciting array of novel targeted therapies. Here, we review the mechanism of action of these emerging therapies and how, with clinical translation, they can potentially improve the survival rates for osteosarcoma patients in the near future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect